Finally, the loss of Cdx2 is associated with stage II/III CRC patients at high risk of disease progression; such patients have also been shown to benefit from adjuvant chemotherapy, underscoring Cdx2 status as a biomarker [10]. Here, CDX2 is linked to colorectal carcinoma.